MAPT and Alzheimer disease: Furthermore, prominent tracer retention is observed in sites susceptible to tau deposition in non-AD tauopathies such as CBD and PSP (Chiotis et al., 2016; Kikuchi et al., 2016; Ishiki et al., 2017).